Overview
- Shares closed at $22.40 on the first day of trading, up 24% from the $18 offer price, for a market value of roughly $1.2 billion.
- Aktis sold 17,650,000 shares at $18 each to raise approximately $318 million, with an additional 30-day overallotment option available to underwriters.
- Eli Lilly purchased about $100 million of the offering, a commitment that enabled the upsized deal from earlier plans.
- The stock trades on the Nasdaq under the symbol AKTS, with the offering expected to close on January 12 subject to customary conditions.
- Aktis is advancing miniprotein radioconjugates led by Nectin-4–targeting AKY-1189, with a Phase 1 readout anticipated in the first quarter of 2027, alongside a broader collaboration with Lilly.